Systematic review and meta-analysis of procalcitonin diagnostic accuracy in community-acquired bacteraemia
This systematic review and meta-analysis assessed the diagnostic accuracy of procalcitonin for community-acquired bacteraemia in adults. The analysis included data from 40 studies involving 192 529 patients, though 32 of these studies were judged to have a high risk of bias. Funding or conflicts of interest were not reported for this publication.
The primary outcome measured diagnostic accuracy using sensitivity, specificity, and the area under the summary receiver-operating curve. At a 0.10-ng/mL threshold, the pooled sensitivity was 93% with a 95% CI of 85-97%. The specificity was 36% with a 95% CI of 26-47%. The area under the summary receiver-operating curve for all studies was 0.80 with a 95% CI of 0.76-0.83% and a prediction interval of 0.57-0.91.
The authors note that a low cut-off value of procalcitonin can be useful to exclude community-acquired bacteraemia. This utility depends on the acceptable trade-off between sensitivity and specificity that the treating clinician considers. Procalcitonin may require combination with clinical characteristics for accurate assessment of bacteraemia risk and safely reducing unnecessary blood cultures. Follow-up duration was not reported in the source data.